Johnson & Johnson is reportedly in advanced talks to acquire Protagonist Therapeutics, a pivotal move that could reshape its immunology and rare blood disorder pipeline. This acquisition would bring the highly anticipated icotrokinra, a potential blockbuster, and the promising rare blood cancer drug rusfertide under J&J’s umbrella, strategically fortifying its position as its flagship immune treatment Stelara faces growing generic competition.
Reports from the Wall Street Journal and Reuters indicate that pharmaceutical giant Johnson & Johnson is engaged in discussions to acquire Protagonist Therapeutics Inc. The news, initially reported on Friday, October 10, 2025, sent Protagonist’s shares soaring, reflecting the high stakes involved in this potential deal for the biotechnology sector. This move aligns with J&J’s ongoing strategy of significant mergers and acquisitions, following its substantial $14.6 billion purchase of Intra-Cellular Therapies earlier this year for its schizophrenia and bipolar treatment, Caplyta.
A Deepened Partnership: From Collaboration to Acquisition
The relationship between Johnson & Johnson and Protagonist Therapeutics is not new. The companies have been long-standing partners, initially collaborating in 2017 to codevelop therapies for immune conditions. This partnership was further expanded in 2021, granting J&J exclusive commercialization rights to one of Protagonist’s most promising assets, icotrokinra.
The potential acquisition signifies J&J’s intent to fully integrate Protagonist’s innovative pipeline, moving beyond a collaborative framework to full ownership. This strategic alignment underscores the importance of securing novel assets that can drive future growth and maintain market leadership in competitive therapeutic areas.
Icotrokinra: J&J’s Next Immunology Blockbuster?
At the heart of the proposed deal is icotrokinra, a targeted oral peptide designed to selectively block the interleukin-23 (IL-23) receptor. This drug candidate has generated significant excitement within the immunology community, particularly for its potential in treating various immune-mediated inflammatory conditions. Currently, icotrokinra is undergoing review by both the FDA and European regulatory bodies for plaque psoriasis.
Beyond psoriasis, the therapeutic reach of icotrokinra extends to other critical areas, including psoriatic arthritis and ulcerative colitis, for which it is also being studied. Analysts, such as those at Jefferies, have pegged icotrokinra as a potential blockbuster, estimating peak sales of up to $7.5 billion in the U.S. alone, as reported by FierceBiotech. Its recent clinical triumph over Bristol Myers Squibb’s oral psoriasis champion Sotyktu has further cemented its reputation as a formidable contender in the crowded immunology market.
Addressing the Stelara Patent Cliff
The timing of this potential acquisition is crucial for Johnson & Johnson. Its highly successful immune treatment, Stelara, a long-standing revenue driver for the company, is facing impending competition from lower-cost biosimilar copycats. This situation creates a significant imperative for J&J to replenish and strengthen its immunology portfolio with new, high-potential assets.
The full acquisition of Protagonist Therapeutics would provide J&J with direct ownership of icotrokinra, offering a timely solution to offset potential revenue losses from Stelara’s patent expiration. This strategic maneuver is not just about replacing revenue; it’s about pioneering the next generation of immunology treatments and maintaining J&J’s leadership in this vital therapeutic space, according to insights from Reuters.
Expanding Horizons: Rusfertide and Rare Blood Disorders
Beyond immunology, the acquisition would also grant J&J access to Protagonist’s promising blood disorder medication, rusfertide. Protagonist currently holds a partnership with Takeda Pharmaceutical for rusfertide, a drug designed to treat a rare blood cancer known as polycythemia vera.
Rusfertide has demonstrated significant success in Phase 3 trials, effectively reducing the need for blood procedures in patients with polycythemia vera. While J&J possesses a robust hematology profile across several blood cancers, its offerings in rare blood disorders are less extensive. Integrating rusfertide into its pipeline would significantly expand J&J’s presence in this underserved therapeutic area, diversifying its portfolio and addressing unmet patient needs. This move highlights J&J’s commitment to broadening its therapeutic scope, as detailed by The Wall Street Journal.
Financial Implications and Market Reaction
Reports suggest that a deal to acquire Protagonist Therapeutics would likely value the company well above its market capitalization of over $4 billion as of Thursday’s close. The speculation surrounding the acquisition has already significantly impacted Protagonist’s stock. Its shares surged by as much as 39% on the day the news broke, marking its most substantial single-day jump since March, and continuing a year-long trend that saw its stock appreciate by 74% through Thursday’s close.
For shareholders and the broader market, such a substantial premium reflects the perceived value of Protagonist’s pipeline, particularly the blockbuster potential of icotrokinra and the strategic fit with J&J’s long-term objectives. J&J’s current share price stood at $154.60 at the time of the reports.
The Long-Term Impact for Patients and Biotech Innovation
From a patient perspective, the acquisition by a pharmaceutical powerhouse like Johnson & Johnson could accelerate the development and global accessibility of drugs like icotrokinra and rusfertide. J&J’s extensive resources, regulatory expertise, and global commercialization capabilities could bring these innovative therapies to more patients faster, potentially improving outcomes for those suffering from debilitating immune conditions and rare blood disorders.
For the biotech industry, this acquisition underscores a growing trend where larger pharmaceutical companies seek to acquire innovative, smaller biotechs with late-stage clinical assets. This strategy offers a pathway for big pharma to rejuvenate their pipelines, mitigate risks associated with internal R&D, and secure future revenue streams in an increasingly competitive landscape. It also highlights the critical role of early-stage collaborations in paving the way for eventual full integration, fostering a dynamic ecosystem of innovation and partnership.
